Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1835586rdf:typepubmed:Citationlld:pubmed
pubmed-article:1835586lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:1835586lifeskim:mentionsumls-concept:C0024305lld:lifeskim
pubmed-article:1835586lifeskim:mentionsumls-concept:C1514474lld:lifeskim
pubmed-article:1835586lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1835586lifeskim:mentionsumls-concept:C2348519lld:lifeskim
pubmed-article:1835586lifeskim:mentionsumls-concept:C1517067lld:lifeskim
pubmed-article:1835586pubmed:issue10lld:pubmed
pubmed-article:1835586pubmed:dateCreated1992-1-9lld:pubmed
pubmed-article:1835586pubmed:abstractTextIn a Danish population-based non-Hodgkin lymphoma (NHL) registry, 1257 newly diagnosed NHL cases were registered over a 5-year period. Of these, 463 (37%) were extranodal. The gastrointestinal tract was the most common site of extranodal involvement (30% of the cases). Histologically, 44% of all extranodal NHL cases had high-grade, 17% intermediate and 27% low-grade features, while 12% were unclassified. The most common histological subtype (Kiel) was the centroblastic diffuse (23% of cases). 50% of all extranodal NHL were localised (stage IE or IIE) and 27% had B symptoms. Site-specific features included a strong age-correlation for thyroid and testes lymphoma (greater than 50 years) and a high prevalence of female cases in thyroid and salivary glands lymphomas (M/F 0.14 and 0.30, respectively). Overall 7-year survival for extranodal NHL was 46% (median 4.9 years). Poor prognosis patients could be identified by the presence of one or more of the following presentation characteristics: age greater than 65 years, B symptoms, high-grade histology, disseminated disease, elevated s-IgA and hyperuricaemia. Relative risk values ranged from 2.1 for age and B symptoms to 1.7 for hyperuricaemia.lld:pubmed
pubmed-article:1835586pubmed:languageenglld:pubmed
pubmed-article:1835586pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1835586pubmed:citationSubsetIMlld:pubmed
pubmed-article:1835586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1835586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1835586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1835586pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1835586pubmed:statusMEDLINElld:pubmed
pubmed-article:1835586pubmed:issn0959-8049lld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:AndersenEElld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:PedersenN TNTlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:ChristensenB...lld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:JohansenPPlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:BrinckerHHlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:PedersenMMlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:JensenM KMKlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:HastrupJJlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:ThorlingKKlld:pubmed
pubmed-article:1835586pubmed:authorpubmed-author:d'AmoreFFlld:pubmed
pubmed-article:1835586pubmed:issnTypePrintlld:pubmed
pubmed-article:1835586pubmed:volume27lld:pubmed
pubmed-article:1835586pubmed:ownerNLMlld:pubmed
pubmed-article:1835586pubmed:authorsCompleteNlld:pubmed
pubmed-article:1835586pubmed:pagination1201-8lld:pubmed
pubmed-article:1835586pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:meshHeadingpubmed-meshheading:1835586-...lld:pubmed
pubmed-article:1835586pubmed:year1991lld:pubmed
pubmed-article:1835586pubmed:articleTitleClinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group.lld:pubmed
pubmed-article:1835586pubmed:affiliationDepartment of Haematology, Odense University Hospital, Denmark.lld:pubmed
pubmed-article:1835586pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1835586lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1835586lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1835586lld:pubmed